share_log

Aquila Solutions Announces Support for FDA ECTD 4.0 Submissions

Aquila Solutions Announces Support for FDA ECTD 4.0 Submissions

Aquila Solutions宣佈支持FDA ECTD 4.0提交
PR Newswire ·  10/08 20:44

WARNER ROBINS, Ga., Oct. 8, 2024 /PRNewswire/ -- Aquila Solutions, a leader in regulatory and pharmaceutical management consulting, is excited to announce the acceptance of Electronic Common Technical Document (eCTD) 4.0 submissions by the U.S. Food and Drug Administration (FDA). As part of its commitment to innovation and regulatory compliance, Aquila Solutions is fully prepared to support clients transitioning to the new eCTD 4.0 format, which represents a major leap forward in global regulatory submissions.

喬治亞州沃納羅賓斯,2024年10月8日/美通社/ - Aquila Solutions,一家在監管和藥品管理諮詢領域領先的公司,非常高興地宣佈美國食品藥品監督管理局(FDA)接受電子公共技術文件(eCTD)4.0版本的申請。作爲承諾創新和符合監管要求的一部分,Aquila Solutions已經充分準備好支持客戶過渡到新的eCTD 4.0格式,這代表了全球監管申請的重大進步。

Aquila Solutions
Aquila Solutions

The eCTD 4.0 format introduces enhanced capabilities for managing complex data structures and offers greater flexibility in the regulatory submission process. With eCTD 4.0, sponsors benefit from improved versioning, lifecycle management, and enhanced metadata functionality. Aquila Solutions is at the forefront of these advancements, providing services that enable pharmaceutical and biologic companies to navigate this transition smoothly while maintaining full compliance with FDA guidelines.

eCTD 4.0格式引入了增強的數據結構管理能力,並提供更大的靈活性,用於監管提交流程。通過eCTD 4.0,贊助商從改進的版本控制、生命週期管理和增強的元數據功能中受益。 Aquila Solutions位於這些進步的最前沿,提供能夠使製藥和生物公司順利過渡並全面符合FDA指南的服務。

What eCTD 4.0 Means for Drug Application Sponsors

eCTD 4.0對藥品申請贊助商意味着什麼

eCTD 4.0 brings a new standard for submitting, updating, and reviewing regulatory documents. It includes significant changes such as:

eCTD 4.0引入了新的標準,用於提交、更新和審核監管文件。它包括重大變化,例如:

  • Enhanced Lifecycle Management: Improved mechanisms for managing and tracking document versions, helping sponsors ensure accurate and up-to-date submissions.
  • Metadata-Driven Submissions: More detailed metadata allows for better organization and more efficient submission review processes.
  • Global Compatibility: eCTD 4.0 aligns with international regulatory frameworks, enabling sponsors to streamline their submissions across multiple regions.
  • 增強的生命週期管理:改進的機制用於管理和跟蹤文件版本,幫助贊助商確保準確和最新的提交。
  • 基於元數據的提交:更詳細的元數據可確保更好的組織結構和更高效的提交審核流程。
  • 全球兼容性:eCTD 4.0與國際監管框架一致,使贊助商能夠在多個地區簡化其提交流程。

Aquila Solutions is fully equipped to assist clients in understanding and leveraging these features. With a suite of services ranging from eCTD publishing to consulting, Aquila Solutions ensures that submissions meet the rigorous standards set by the FDA and other global regulatory authorities.

Aquila Solutions已經做好充分準備,幫助客戶理解和利用這些特色。從eCTD出版到諮詢等一系列服務,Aquila Solutions確保提交內容符合FDA和其他全球監管機構制定的嚴格標準。

Altair eCTD Viewer: Supporting eCTD 4.0

Altair eCTD Viewer:支持eCTD 4.0

To further support the adoption of eCTD 4.0, Aquila Solutions offers the Altair eCTD Viewer, an advanced tool that allows drug application sponsors to review their submissions exactly as the FDA reviewers do. With Altair, sponsors can easily navigate through the intricate folder structures, access detailed PDF documents, and track submission sequences. Altair supports unlimited sequences, preserving the integrity of eCTD content while providing valuable insights into the overall impact of each sequence.

爲進一步支持eCTD 4.0的採用,Aquila Solutions推出Altair eCTD Viewer,這是一種先進工具,允許藥物申請贊助商像FDA審閱人員一樣審閱他們的提交內容。使用Altair,贊助商可以輕鬆瀏覽複雜的文件夾結構,查看詳細的PDF文檔,並跟蹤提交順序。Altair支持無限順序,保持eCTD內容的完整性,同時提供有關每個順序整體影響的寶貴見解。

As eCTD 4.0 is adopted, Altair's ability to handle complex data structures ensures that sponsors remain compliant with evolving regulatory requirements. The viewer's user-friendly interface, combined with powerful audit trails and comprehensive document tracking, provides sponsors with an unparalleled submission management experience.

隨着eCTD 4.0的採用,Altair處理複雜數據結構的能力確保贊助商始終遵守不斷髮展的監管要求。查看器的用戶友好界面,結合強大的審計跟蹤和全面的文件跟蹤,爲贊助商提供無與倫比的提交管理體驗。

Aquila Solutions' Expertise in Regulatory Submissions

Aquila Solutions在監管提交領域的專業知識

Since 2010, Aquila Solutions has specialized in offering comprehensive regulatory services, including eCTD regulatory publishing, SPL authoring, and consulting tailored to meet the needs of small to medium-sized pharmaceutical and biologic companies. As a recognized leader in regulatory compliance, Aquila Solutions helps clients navigate complex regulatory environments, reducing risks and accelerating time-to-market for new drugs and therapies.

自2010年以來,Aquila Solutions專門提供全面的監管服務,包括eCTD監管出版、SPL創作和諮詢,旨在滿足中小型藥品和生物公司的需求。作爲監管合規性的知名領導者,Aquila Solutions幫助客戶應對複雜的監管環境,降低風險,加速新藥物和療法上市的時間。

Aquila Solutions' expertise extends across global regulatory frameworks, including FDA, Health Canada, and the European Medicines Agency (EMA), ensuring that clients' submissions are accepted and reviewed in all key markets. With the introduction of eCTD 4.0, Aquila Solutions is committed to supporting clients through every step of the regulatory submission process, providing the tools, knowledge, and support needed to succeed.

Aquila Solutions的專業知識涵蓋全球監管框架,包括FDA、加拿大衛生部和歐洲藥品管理局(EMA),確保客戶的提交內容在所有關鍵市場獲得接受和審查。隨着eCTD 4.0的推出,Aquila Solutions致力於在監管提交流程的每一步支持客戶,提供成功所需的工具、知識和支持。

About Aquila Solutions

關於 Aquila Solutions

Founded in 2010, Aquila Solutions continues to lead the way in providing innovative regulatory and pharmaceutical management consulting services to small and medium pharmaceutical and biologic companies. With a focus on delivering practical solutions that drive regulatory success, Aquila Solutions remains dedicated to supporting clients with their products and services. You can learn more about Aquila Solutions at .

Aquila Solutions 成立於 2010 年,繼續領先提供創新的規制和藥品管理諮詢服務,面向小型和中型製藥和生物公司。專注於提供推動規制成功的實際解決方案,Aquila Solutions 致力於爲客戶提供其產品和服務支持。您可以在 網站上了解 Aquila Solutions 的更多信息。

Contact Information

聯繫信息

Josh Boutwell
[email protected]
404) 496-4171

Josh Boutwell
[email protected]
404) 496-4171

SOURCE Aquila Solutions

SOURCE Aquila Solutions

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力
9k+
9k+

Digital Media
數字媒體

Outlets
賣場
270k+
270k+

Journalists
新聞記者

Opted In
已選擇加入
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論